Purpose To differentiate benign from malignant bone tumors by analyzing the vascular distribution within bone tumors with dynamic contrast-enhanced MRI. Methods We studied dynamic contrast-enhanced MRI for 49 bone tumors (22 malignant and 27 benign tumors). Seven small regions of interest (ROI) were set inside the largest portion of each tumor. Four ROI were placed evenly on the periphery and three ROI were placed evenly on the line of the longest breadth within the tumor. The slope of the curve (%Slope) was calculated on the time-intensity curves of the whole tumor and of each ROI. The variance values for the %Slope of the ROI were calculated to assess the dispersion of the intensity change at each ROI within the tumor. Results Mean value of the %Slopes of whole tumor regions for malignant bone tumors (70.4 ± 60.3%) was significantly higher than that for benign bone tumors (37.6 ± 52.9%) (P = 0.015), although giant cell tumor (GCT), a locally aggressive tumor, had a relatively higher %Slope. Mean value of the variance of %Slopes for malignant bone tumors (3485.9 ± 5942.5) was significantly higher than that for all benign tumors (470.4 ± 583.9) (P = 0.012), indicating that the %Slope values of seven ROI within malignant bone tumors varied more widely compared with the ROI inside benign bone tumors. GCT also demonstrated a lower value. Conclusion Our method of analyzing the signal intensity change at seven separate regions that evaluates the vascular distribution within a tumor could be a useful tool for differentiating between benign and malignant bone tumors.
Introduction
Magnetic resonance imaging (MRI) has an important role in the diagnosis and management of patients with bone tumors (Zimmer et al. 1985; Pettersson et al. 1987; Bloem et al. 1988; Hoffer et al. 2000) . MRI directly demonstrates a lesion relative to the surrounding normal structures with accurate anatomical detail. Although various reports have been designed to characterize bone tumors through MRI, results have been controversial (Lang et al. 1998) . The ability of static clinical MRI to depict tumor viability is limited by several factors: (1) T1-weighted MRI alone cannot differentiate viable tumor from non-viable tissue or edema (Holscher et al. 1990 ), (2) T2-weighted MRI cannot adequately distinguish tumor from necrosis, and lesion boundaries are frequently overestimated because of the presence of edema and hemorrhage (Pan et al. 1990; Sanchez et al. 1990; Brisse et al. 2004) , and (3) static T1-weighted contrast media-enhanced MRI can differentiate necrosis and hemorrhage from viable tumor but has difficulty separating viable tumor from surrounding inflammation (Erlemann et al. 1990; Verstraete and Lang 2000) .
Dynamic contrast-enhanced MRI is a method of physiologic imaging that evaluates the early enhancement kinetics of water-soluble MR contrast media and shows the signal intensity of a region in real time (Erlemann et al. 1989) . Faster contrast enhancement is suitable for visualizing increased vascularity such as capillary permeability and viable tumor, whereas slower enhancement demonstrates less vascular areas such as non-viable tumor, tissue necrosis and inflammation (Kormano and Dean 1976; Verstraete et al. 1995) . Dynamic contrast-enhanced MRI is expected to be excellent for assessing response to chemotherapy compared with conventional static MRI because it can assess tumor vascularity that may indicate viability of malignant bone tumors (Erlemann et al. 1990; Fletcher et al. 1992; Kawai et al. 1997; Egmont-Petersen et al. 2000) . Despite its usefulness for assessing the therapeutic effect on bone sarcomas, it is still controversial as to whether dynamic contrast-enhanced MRI can differentiate malignant bone tumors from benign bone tumors.
Previous papers demonstrated that the time-course change of intensity can suggest the malignancy of bone tumors with a 60-80% sensitivity (Verstraete et al. 1994b; Bloem et al. 1997; Geirnaerdt et al. 2000) . This may be the reason why these papers set the region of interest (ROI) over the entire tumor area imaged in order to examine the intensity change. There are various tissues and fluids within malignant bone tumors, such as high-grade tumor tissue, necrotic and edematous tissue, hemorrhage, and inflammation. One ROI set covering the entire area of a tumor may not be appropriate for evaluating vascularity within a tumor since the intensity change over the whole tumor can be averaged. For studying vascularity of bone tumors, it would be more reliable to designate several ROI sets inside the tumor as seen on MRI and to evaluate each of them. In the present study, we examined the intensity change of seven ROI sets within the tumor boundaries as determined with dynamic MRI and assessed their values for differentiating the malignancy of bone tumors.
Patients and methods

Patients
Forty-nine patients with primary bone tumors were studied using dynamic contrast-enhanced MRI during the preoperative routine examination before initial treatment (Table 1) . Diagnosis of all patients was made by histological examination. The patients consisted of 32 males and 17 females with a mean age of 30 years (4-74 years). Twentyfour tumors were of the femur, seven of the tibia, four of the humerus, three of the pelvis, two of the fibula, and nine were from other locations. There were 22 malignant bone tumors, consisting of 15 osteosarcoma, 3 chondrosarcoma, 2 Ewing's sarcoma, 1 malignant fibrous histiocytoma (MFH) and 1 cordoma. There were also 27 benign bone tumors consisting of 5 giant cell tumors (GCT), 5 enchondroma, 4 chondroblastoma, 2 osteochondroma, 2 non ossifying fibroma, 2 aneurysmal bone cysts, 2 eosinophilic granuloma, 2 fibrous dysplasia, 2 solitary bone cysts and 1 osteofibrous dysplasia.
Dynamic contrast-enhanced MRI study All MR examinations were performed using a 0.5 T (Flexart Hyper; Toshiba, Tokyo, Japan) clinical imager. A quadrature detection (QD) body coil was used for pelvic and femoral imaging, and a 20 cm circular surface coil was adapted for imaging the other locations.
Prior to dynamic contrast-enhanced MRI study, we performed the following pulse sequences: axial, coronal, and sagital T1-weighted spin echo imaging: repetition time (TR), 550 ms; echo time (TE), 15 ms; number of excitations (NEX), 1.7; slice thickness, 5-10 mm, field of view (FOV), 20-35 cm; matrix size, 192 · 256; acquisition time, 6 min, axial, coronal, and sagital T2-weighted fast spin echo imaging: TR, 4,000 ms; TE, 102 ms; echo train length, 13; NEX, 3; slice thickness, 5-10 mm; FOV, 20-35 cm; matrix size, 192 · 256; acquisition time, 6 min 4 s.
For a dynamic contrast-enhanced MRI, imaging plane was selected based on obtaining the largest and most representative area of the tumor. Immediately after the first sequence, a bolus injection of gadolinium diethylene triamine pentaacetic acid (Gd-DTPA) (0.1 mmol/kg) was administered intravenously followed by ultra-fast sequences using a field echo sequence (TR, 70 ms; TE, 5 ms; flip angle, 70°; NEX, 1; slice thickness, 10 mm; FOV, 20-35 cm; matrix size, 128-192 · 256; echo delay time, 20 ms) at intervals of 13 s for 5 min. The signal intensity of the largest portion of the tumor was measured and plotted against time. The progression of enhancement was subjectively classified into three groups according to the shape of the time-signal intensity curve by modified classification reported previously (van der Woude et al. 1998b) and described in Fig. 1 . In the analysis of dynamic MRI, we hypothesized that Type I (rapid pattern) was indicative of malignant lesions, and type II (slow pattern) and type III (flat pattern) were indicative of benign lesions. Seven regions of interest (ROI) were set within the largest portion of the tumor. Four ROI were placed evenly on the periphery of the largest portion of the tumor, and three ROI were placed evenly on the line of the longest breadth within the tumor (Fig. 2) . The signal intensity of each of the seven ROI set inside the tumor were also plotted against time on the time-intensity curve.
The slope of the curve (%Slope), which shows the percent increase in signal intensity per minute over the baseline value, was derived by using the following formula (Erlemann et al. 1990; Hanna et al. 1992) (Fig. 3) :
signal intensity demonstrated at a timepoint of T max , SI base : signal intensity before the injection of Gd-DTPA, T max : first timepoint at which the sum of the next two consecutive %Slope values becomes less than 10% per minute, T base : timepoint immediately preceding signal intensity increase.
The variance values for %Slope of the seven ROI set inside the tumor were calculated to assess the dispersion of the intensity change at each of these ROI, which could indicate the heterogeneity of the vascularity within the tumor.
Statistical analysis
The Mann-Whitney U test was used to evaluate the difference in %Slope and the variance value for %Slope. The (1998b) . Type I curve (rapid pattern): early onset of enhancement followed by rapidly progressive linear increase of signal intensity (represented by a steep slope, parallel to the arterial curve) to an early maximum followed by a distinct transition to a stable level of signal intensity. Type II curve (slow pattern): steady increase or flattening of the curve after the steepest part of the time-signal intensity curve. Type III curve (flat pattern): linear enhancement with a very low slope, representing slow or absent enhancement, similar to a curve representing normal muscle. In the analysis of dynamic MRI, we hypothesized that Type I curve was indicative of malignant lesions, and Type II and III curves were indicative of benign lesions level of significance was chosen at P < 0.05. All data was calculated and evaluated using Statview 5.0J software (SAS Institute Inc., Cary, NC, USA).
Results
Seventeen of 22 malignant bone tumors and 6 of 27 benign bone tumors resulted in the Type I pattern (Table 2) . Those 6 benign tumors with Type I pattern consisted of four GCT and two chondroblastoma. Type II pattern was found in 17 benign bone tumors and 4 of 22 malignant bone tumors, which included 2 osteosarcoma and 2 chondrosarcoma. There were four benign bone tumors and one chordoma demonstrating the Type III pattern. Seventeen of 22 malignant bone tumors revealed rapid pattern (Type I curve), and 21 of 27 benign bone tumors demonstrated slow or flat pattern (Type II or III curve). Differentiation of benign from malignant bone tumors based on the timeintensity curve was possible with a sensitivity of 77% and a specificity of 78%. Table 3 demonstrates each %Slope value representing a whole tumor area with dynamic contrast-enhanced MRI. The mean value of %Slopes for malignant bone tumors (70.4 ± 60.3%) was significantly higher than that for benign bone tumors (37.6 ± 52.9%) (P = 0.015, Mann- Whitney U test). Moreover, this significant difference was even more pronounced (15.8 ± 14.3%) (P < 0.0001) when the mean value of %Slopes for GCT (133.4 ± 4.7%) was not counted among the benign bone tumors since the %Slopes for GCT was comparatively higher than the other benign bone tumors. Chordoma, one of the malignant bone tumors, had a lower mean value of %Slope than most of benign tumors.
The variance values for %Slopes of the seven ROI located within a tumor were estimated as the dispersion of intensity change (%Slope) at each ROI of a tumor. Table 4 shows each variance value for the %Slopes of the seven ROI within each tumor. The mean value of the variance of %Slopes for malignant bone tumors (3485.9 ± 5942.5) was significantly higher than that for all benign tumors (470.4 ± 583.9) (P = 0.012), indicating that %Slope values of the seven ROIs inside a malignant bone tumor varied more widely than the seven ROI within a benign bone tumor. The vascularity of malignant bone tumors was more heterogeneous than that of benign bone tumors. In particular, the mean variance value of %Slope for GCT (1223.7 ± 727.4) was lower than that of high-grade malignant bone tumors such as MFH (4481.4), osteosarcoma (3953.2 ± 6979.6), and Ewing sarcoma (2720.4 ± 1813.9), indicating that the vascularity within a high-grade malignant tumor is more heterogeneous than that of a GCT. Chordoma had the lowest mean value of the variance of %Slope (0.0) among all the bone tumors.
Discussion
Dynamic contrast-enhanced MRI, which is performed by ultra fast MRI after a bolus injection of contrast media, can be used to evaluate blood flow by calculating the signal intensity of a region in real time (Erlemann 1992) , thus indicating the vascularity of a tumor. By analyzing tumor vascularity using dynamic MRI, many authors have shown that the slope value can be useful for indicating bone tumor viability and predicting tumor necrosis in bone sarcomas after chemotherapy (Erlemann et al. 1990; Bonnerot et al. 1992; Fletcher et al. 1992) . Moreover, dynamic contrastenhanced MRI is excellent for depicting anatomical position like a conventional static MRI and has merit in the evaluation of vascularity in an arbitrary section demonstrating the most representative area of the tumor (Lang et al. 1995; Verstraete and Lang 2000) . van der Woude et al. (1998a) performed dynamic enhanced MRI in 175 patients with a musculoskeletal tumor and assessed the interval between arterial enhancement and onset of tumor enhancement, the pattern (peripheral or diffuse) of initial enhancement, and the shape of the timesignal intensity curve. They concluded that benign bone tumors could not be accurately differentiated from malignant bone tumors on the basis of their defined parameters (sensitivity, 63-76%; specificity, 50-76%). Our study also showed that it was possible, with a sensitivity of 77% and specificity of 78%, to differentiate benign from malignant bone tumors based on the time-intensity curve at one section of a tumor. Bloem et al. (1997) have reported in a review article concerning MRI for patients with musculoskeletal tumors that not only viable malignant tumors, but also biologically active benign lesions such as eosinophilic granuloma, osteoid osteoma, osteoblastoma, chondroblastoma and GCT displayed rapid-enhancement time-intensity curves of dynamic contrast-enhanced MRI. Furthermore, they reported that not only most benign lesions, but also low-grade chondrosarcoma and sclerotic osteosarcoma, displayed low-enhancement time-intensity curves. We obtained similar results in our series. Our results demonstrated that the mean value of the %Slopes for malignant bone tumors (70.4 ± 60.3%) was significantly higher than that for benign bone tumors (37.6 ± 52.9%). Verstraete et al. (1994b) reported that a significant difference was found in the slope values of dynamic contrast-enhanced MRI between malignant and benign musculoskeletal tumors. However, they indicated that dynamic contrast-enhanced MRI could depict tissue vascularization and perfusion rather than actual benignity or malignancy since there was an overlap in the slope values of highly vascular benign lesions and malignant lesions.
GCT, the most common benign tumor in our series, had the highest mean value of %Slope (133.4) among all the bone tumors. Verstraete et al. (1994a) also demonstrated same result that GCT showed the highest mean value of %Slope among all musculoskeletal tumors. Chordoma, one of low-grade malignant bone tumors, had much lower mean value of %Slope (7.4) than the average of benign bone tumors (37.6). van der Woude et al. (1998b) showed that only 6 of 26 low-grade malignant tumors showed a Type I curve. There was also a considerable overlap of %Slope value between aggressive benign bone tumors and low-grade malignant tumors.
As mentioned above, the overall rate of enhancement is not a reliable indicator of a benign versus a malignant bone lesion. As a method for evaluating any difference in enhancement within a tumor, Ma et al. have reported that the rim-to-center differential enhancement ratio can potentially be used to differentiate benign from malignant bone tumors (Ma et al. 1997) . The increased rim enhancement with delayed center enhancement, which indicated a solid, malignant mass of bone, might be due, in part, to the high internal, interstitial pressure exhibited by malignant neoplasms but not benign tumors. There are generally some necrotic areas and/or undifferentiated lesions with aggressive tumor tissue inside a malignant tumor mass, indicating that the inside of a malignant tumor can be vascularly heterogeneous. The rim-to-center enhancement cannot be enough to reflect the vascular heterogeneity inside the tumor.
In order to study the vascular heterogeneity inside a tumor, we set up seven small ROI within each tumor and calculated the intensity change of each ROI. We considered the variance value for slopes of the seven ROI as the dispersion of the blood flow at each ROI, which demonstrated the heterogeneity of vascularity inside the tumor. The distribution of slope values in malignant bone tumors was significantly higher than that in benign tumors. This suggested that the malignant bone tumors were composed of regions having various changes of signal intensity, indicating that the viability inside malignant tumors was heterogeneous. Therefore, seven ROI could also be useful for determining the optimum site for biopsy.
Chordoma, one of low-grade malignant tumors, had the lowest mean value of the variance of %Slopes among all the bone tumors in the present study. This might be the reason why chordoma was only one case in our series and showed very low vascularity within the tumor. Because the number of each tumor type is small (n = 1-5), except for osteosarcoma (n = 15) in the present study, prospective studies that include larger numbers of patients are needed to validate the use of our analyzing method.
In conclusion, the signal intensity change observed with dynamic contrast-enhanced MRI can be used to assess the vascularity of a tumor. Previous papers showed that the intensity change over a whole tumor section can predict the viability of the tumor, but this method was not enough to determine the malignancy of bone tumors. Our method of analysis looking at the intensity change at seven separate regions can indicate the heterogeneity of vascularity within a tumor, which could make our method useful for differentiating between benign and malignant bone tumors.
